The direct cost of seizure events in severe childhood-onset epilepsies: A retrospective claims-based analysis

Abstract

ObjectiveThe objective of the study was to assess the direct cost of medically treated seizure events in severe childhood-onset epilepsies. Lennox–Gastaut syndrome (LGS), Dravet syndrome (DS), and tuberous sclerosis complex (TSC) are representative conditions associated with frequent intractable seizures. MethodsCommercial and Medicaid insurance claims from 2010 to 2015 were queried to identify patients with possible LGS, possible DS, or TSC, having ≥2 years of continuous insurance from the date of first epilepsy/seizure diagnosis or antiepileptic drug (AED) fill (index date). Utilization and cost data in patients with and without seizure events requiring acute treatment were evaluated for two years postindex. Medically treated seizure events resulting in minor, moderate, severe, and no injury were included. Average costs were normalized to 2017 dollars at 3% per annum and reported for each cohort, by insurance type and degree of injury. ResultsAmong 9754 patients, 55.4–58.8% of LGS, 47.7–55.8% of DS, and 13.7–28.0% of TSC cohorts had ≥1 medically treated seizure event, depending on insurance type. Events during two-year postindex averaged 2.8–3.3 in LGS, 3.1–3.3 in DS, and 1.9–2.2 in TSC; cost per event averaged $8147–$14,759 in LGS, $4637–$8751 in DS, and $5335–$9672 in TSC. In patients with events, average all-cause costs per-patient-per-year (PPPY) were $71,512–$84,939 in LGS; $31,278–$43,758 in DS; and $42,997–$48,330 in TSC. ConclusionsPatients with intractable seizures having at least one medically treated seizure event incur substantial all-cause costs. Our results can be used to inform cost effectiveness and budget impact models to estimate the value of existing and future treatments for these and similar conditions.